Oncolytics Biotech Announces New Clinical Trial for Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

Reuters12-16

Oncolytics Biotech Announces New Clinical Trial for Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

Oncolytics Biotech Inc. has announced promising clinical and translational data supporting the development of its immunotherapy candidate, pelareorep, for use in second-line treatment of metastatic colorectal cancer (mCRC), specifically targeting patients with KRAS-mutant, microsatellite-stable disease. The data, which have already been presented, indicate a 33% overall response rate $(ORR)$ in this challenging patient subgroup. Based on these findings, Oncolytics plans to initiate a controlled clinical study to further evaluate pelareorep's efficacy in KRAS-mutant MSS mCRC. The company intends to sponsor the study to maintain full analytical rigor and data control, with the goal of supporting future regulatory submissions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251216336013) on December 16, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591980334?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591980334","market":"nz","top_or_hot":-1,"title":"Oncolytics Biotech Announces New Clinical Trial for Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Oncolytics Biotech Announces New Clinical Trial for Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ONCWF\">Oncolytics Biotech Inc.</a> has announced promising clinical and translational data supporting the development of its immunotherapy candidate, pelareorep, for use in second-line treatment of metastatic colorectal cancer (mCRC), specifically targeting patients with KRAS-mutant, microsatellite-stable disease. The data, which have already been presented, indicate a 33% overall response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> in this challenging patient subgroup. Based on these findings, Oncolytics plans to initiate a controlled clinical study to further evaluate pelareorep's efficacy in KRAS-mutant MSS mCRC. The company intends to sponsor the study to maintain full analytical rigor and data control, with the goal of supporting future regulatory submissions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ONCY\">Oncolytics Biotech Inc</a>. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251216336013) on December 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oncolytics Biotech Announces New Clinical Trial for Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncolytics Biotech Announces New Clinical Trial for Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-16 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Oncolytics Biotech Announces New Clinical Trial for Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ONCWF\">Oncolytics Biotech Inc.</a> has announced promising clinical and translational data supporting the development of its immunotherapy candidate, pelareorep, for use in second-line treatment of metastatic colorectal cancer (mCRC), specifically targeting patients with KRAS-mutant, microsatellite-stable disease. The data, which have already been presented, indicate a 33% overall response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> in this challenging patient subgroup. Based on these findings, Oncolytics plans to initiate a controlled clinical study to further evaluate pelareorep's efficacy in KRAS-mutant MSS mCRC. The company intends to sponsor the study to maintain full analytical rigor and data control, with the goal of supporting future regulatory submissions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ONCY\">Oncolytics Biotech Inc</a>. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251216336013) on December 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ONCY","symbol_name":"Oncolytics Biotech Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL2Tj1gz:1","article_id":"2591980334","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591980334","pubTimestamp":1765893694,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Oncolytics Biotech Inc. has announced promising clinical and translational data supporting the development of its immunotherapy candidate, pelareorep, for use in second-line treatment of metastatic colorectal cancer , specifically targeting patients with KRAS-mutant, microsatellite-stable disease. The data, which have already been presented, indicate a 33% overall response rate  in this challenging patient subgroup. Based on these findings, Oncolytics plans to initiate a controlled clinical study to further evaluate pelareorep's efficacy in KRAS-mutant MSS mCRC. The company intends to sponsor the study to maintain full analytical rigor and data control, with the goal of supporting future regulatory submissions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, invest","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ONCY":"Oncolytics Biotech Inc","BK4139":"生物科技"},"translate_title":"Oncolytics Biotech宣布Pelareorep治疗KRAS突变转移性结直肠癌的新临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONCY":0.9},"content_text":"Oncolytics Biotech Announces New Clinical Trial for Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer\n    \n\nOncolytics Biotech Inc. has announced promising clinical and translational data supporting the development of its immunotherapy candidate, pelareorep, for use in second-line treatment of metastatic colorectal cancer (mCRC), specifically targeting patients with KRAS-mutant, microsatellite-stable disease. The data, which have already been presented, indicate a 33% overall response rate $(ORR)$ in this challenging patient subgroup. Based on these findings, Oncolytics plans to initiate a controlled clinical study to further evaluate pelareorep's efficacy in KRAS-mutant MSS mCRC. The company intends to sponsor the study to maintain full analytical rigor and data control, with the goal of supporting future regulatory submissions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251216336013) on December 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591980334","isCrawlerRequest":true}